Lyrica (Pfizer) success in GAD discontinuation symptoms

Pfizer announced top-line results for Lyrica (pregabalin) capsules Study A0081147 � Long Term Safety and Efficacy of Pregabalin in Subjects with Generalized Anxiety Disorder (GAD) �which demonstrate that drug discontinuation symptoms were low after tapering Lyrica treatment following three months and six months in GAD patients. The European Medicines Agency (EMA) requested this study to investigate the relationship between dose and duration of treatment on discontinuation symptoms, including rebound anxiety, following long-term treatment with Lyrica in GAD patients. Pfizer will continue to further analyze these top-line results. Lyrica is approved for the treatment of GAD in adults in the European Union and several other regions around the world, but not in the United States.